Fennec Pharmaceuticals (FENC) Stock Analysis

What Fennec Pharmaceuticals does

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Key metrics

ETFs linked to FENC

Broad-market and Healthcare sector ETFs an investor holding Fennec Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how FENC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Fennec Pharmaceuticals?

Fennec Pharmaceuticals trades under the ticker FENC on NASDAQ.

Which exchange is FENC listed on?

FENC is listed on NASDAQ.

What sector does Fennec Pharmaceuticals operate in?

Fennec Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze FENC in a portfolio?

PortView shows FENC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.